Mga Batayang Estadistika
| LEI | 529900ZIDI5C9C9TTI91 |
| CIK | 1660046 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Immuron Limited - Depositary Receipt (Common Stock)
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| September 2, 2025 |
Exhibit 99.2 |
|
| September 2, 2025 |
Exhibit 99.1 Immuron Limited Appendix 4E Preliminary final report 1. Company details Name of entity: Immuron Limited ABN: 80 063 114 045 Reporting period: For the year ended 30 June 2025 Previous period: For the year ended 30 June 2024 2. Results for announcement to the market $ Revenue from ordinary activities up 48.6% to 7,287,002 Loss from ordinary activities after tax attributable to the membe |
|
| September 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) |
|
| August 26, 2025 |
Immuron partners with InvestorHub Exhibit 99.2 Immuron partners with InvestorHub Melbourne, Australia, August 26, 2025: Immuron Limited (ASX: IMC; NASDAQ: IMRN) advises it has entered into a partnership with InvestorHub, a direct-to-investor engagement software company that provides public companies the digital capabilities to build direct and interactive relationships with investors. In line with the Company’s commitments to bett |
|
| August 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Ind |
|
| August 15, 2025 |
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Exhibit 99.2 Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Announcement Summary Entity name IMMURON LIMITED Date of this announcement Friday August 15, 2025 The +securities the subject of this notification are: +Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX Total number of +securities to be issued |
|
| August 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Ind |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Ind |
|
| August 13, 2025 |
Immuron CEO, Steven Lydeamore to present at Emerging Growth Conference Exhibit 99.2 Immuron CEO, Steven Lydeamore to present at Emerging Growth Conference Melbourne, Australia, August 13, 2025: Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting virtually at the Emerging Growth Conference on Wednesday 20th August 2025 (9:05am - 9:35am U.S. Eastern Time). Mr. Steven Lydeamore, Chief Executive O |
|
| July 21, 2025 |
Notice Under Section 708A(5) of the Corporations Act Exhibit 99.2 Notice Under Section 708A(5) of the Corporations Act Melbourne, Australia, July 21 2025 This notice is given by Immuron Limited (ASX: IMC; NASDAQ: IMRN) under section 708A(5)(e) of the Corporations Act 2001 (the ‘Corporations Act’). Type Shares Class Ordinary ASX code IMC Date of Issue 21 July 2025 Number Issued 32,909,640 The Company gives notice under section 708A(5)(e) of the Corpo |
|
| July 21, 2025 |
Appendix 2A - Application for quotation of securities Exhibit 99.1 Appendix 2A - Application for quotation of securities Announcement Summary Entity name IMMURON LIMITED Announcement Type New announcement Date of this announcement Sunday July 20, 2025 The +securities to be quoted are: +Securities issued as part of a transaction or transactions previously announced to the market in an Appendix 3B Total number of +securities to be quoted ASX +security |
|
| July 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indic |
|
| July 18, 2025 |
Appendix 2A - Application for quotation of securities Exhibit 99.1 Appendix 2A - Application for quotation of securities Announcement Summary Entity name IMMURON LIMITED Announcement Type New announcement Date of this announcement Friday July 18, 2025 The +securities to be quoted are: +Securities issued as part of a transaction or transactions previously announced to the market in an Appendix 3B Total number of +securities to be quoted ASX +security |
|
| July 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indic |
|
| July 18, 2025 |
Notice Under Section 708A(5) of the Corporations Act Exhibit 99.2 Notice Under Section 708A(5) of the Corporations Act Melbourne, Australia, July 18 2025 This notice is given by Immuron Limited (ASX: IMC; NASDAQ: IMRN) under section 708A(5)(e) of the Corporations Act 2001 (the ‘Corporations Act’). Type Shares Class Ordinary ASX code IMC Date of Issue 18 July 2025 Number Issued 473,880 The Company gives notice under section 708A(5)(e) of the Corporat |
|
| July 17, 2025 |
FY25 global sales exceed projection, up 49% on prior year Exhibit 99.2 FY25 global sales exceed projection, up 49% on prior year Sales Highlights (unaudited): Global ● Annual sales AUD$7.3 million up 49% on prior year ● June 2025 Quarter AUD$2.0 million up 55% on prior year Australia ● Annual sales AUD$5.2 million up 40% on prior year ● June 2025 Quarter AUD$1.5 million up 58% on prior year North America ● Annual sales AUD$2.0 million up 76% on prior yea |
|
| July 17, 2025 |
Notice Under Section 708A(5) of the Corporations Act Exhibit 99.2 Notice Under Section 708A(5) of the Corporations Act Melbourne, Australia, July 17 2025 This notice is given by Immuron Limited (ASX: IMC; NASDAQ: IMRN) under section 708A(5)(e) of the Corporations Act 2001 (the ‘Corporations Act’). Type Shares Class Ordinary ASX code IMC Date of Issue 17 July 2025 Number Issued 877,440 The Company gives notice under section 708A(5)(e) of the Corporat |
|
| July 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indic |
|
| July 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indic |
|
| July 17, 2025 |
Appendix 2A - Application for quotation of securities Exhibit 99.1 Appendix 2A - Application for quotation of securities Announcement Summary Entity name IMMURON LIMITED Announcement Type New announcement Date of this announcement Thursday July 17, 2025 The +securities to be quoted are: +Securities issued as part of a transaction or transactions previously announced to the market in an Appendix 3B Total number of +securities to be quoted ASX +securit |
|
| June 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indic |
|
| June 4, 2025 |
Notice Under Section 708A(5) of the Corporations Act Exhibit 99.2 Notice Under Section 708A(5) of the Corporations Act Melbourne, Australia, June 4, 2025 This notice is given by Immuron Limited (ASX: IMC; NASDAQ: IMRN) under section 708A(5)(e) of the Corporations Act 2001 (the ‘Corporations Act’). Type Shares Class Ordinary ASX code IMC Date of Issue 3 June 2025 Number Issued 116,680 The Company gives notice under section 708A(5)(e) of the Corporati |
|
| June 4, 2025 |
Appendix 2A - Application for quotation of securities Exhibit 99.1 Appendix 2A - Application for quotation of securities Announcement Summary Entity name IMMURON LIMITED Announcement Type New announcement Date of this announcement Wednesday June 04, 2025 The +securities to be quoted are: +Securities issued as part of a transaction or transactions previously announced to the market in an Appendix 3B Total number of +securities to be quoted ASX +securi |
|
| May 30, 2025 |
Exhibit 99.3 May 30, 2025 Letter to Shareholders Highlights: ● Immuron on track to exceed A$7 million in Sales this financial year ● Uniformed Services University anticipates topline results of Travelan® clinical study in October 2025 ● Immuron anticipates IMM-529 (Clostridiodes difficile infection) IND submission to the FDA in August 2025 ● Launch plans underway for ProIBS® in Australia ● Immuron |
|
| May 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indica |
|
| May 30, 2025 |
Notice Under Section 708A(5) of the Corporations Act Exhibit 99.2 Notice Under Section 708A(5) of the Corporations Act Melbourne, Australia, May 30, 2025 This notice is given by Immuron Limited (ASX: IMC; NASDAQ: IMRN) under section 708A(5)(e) of the Corporations Act 2001 (the ‘Corporations Act’). Type Shares Class Ordinary ASX code IMC Date of Issue 29 May 2025 Number Issued 135,800 The Company gives notice under section 708A(5)(e) of the Corporati |
|
| May 30, 2025 |
Appendix 2A - Application for quotation of securities Exhibit 99.1 Appendix 2A - Application for quotation of securities Announcement Summary Entity name IMMURON LIMITED Announcement Type New announcement Date of this announcement Friday May 30, 2025 The +securities to be quoted are: +Securities issued as part of a transaction or transactions previously announced to the market in an Appendix 3B Total number of +securities to be quoted ASX +security c |
|
| April 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indi |
|
| April 11, 2025 |
Notice Under Section 708A(5) of the Corporations Act Exhibit 99.3 Notice Under Section 708A(5) of the Corporations Act Melbourne, Australia, April 11, 2025 This notice is given by Immuron Limited (ASX: IMC; NASDAQ: IMRN) under section 708A(5)(e) of the Corporations Act 2001 (the ‘Corporations Act’). Type Shares Class Ordinary ASX code IMC Date of Issue 10 April 2025 Number Issued 179,664 The Company gives notice under section 708A(5)(e) of the Corpo |
|
| April 11, 2025 |
Appendix 2A - Application for quotation of securities Exhibit 99.1 Appendix 2A - Application for quotation of securities Announcement Summary Entity name IMMURON LIMITED Announcement Type New announcement Date of this announcement Friday April 11, 2025 The +securities to be quoted are: +Securities issued, transferred or re-classified as a result of options being exercised or other +convertible securities being converted Total number of +securities to |
|
| April 11, 2025 |
Exhibit 99.2 Appendix 3H - Notification of cessation of securities Announcement Summary Entity name IMMURON LIMITED Announcement Type New announcement Date of this announcement Friday April 11, 2025 Details of +securities that have ceased ASX +security code Security description Number of +securities that have ceased The +securities have ceased due to Date of cessation IMCAE PERFORMANCE RIGHTS 285, |
|
| April 10, 2025 |
Immuron Travelan® highest sales in history Exhibit 99.1 Immuron Travelan® highest sales in history Sales Highlights (unaudited): Global · Immuron exceeds AUD$5 million in sales in a fiscal year - highest sales in history · March 2025 Quarter AUD$1.3 million up 2% on prior year · March 2025 Year to Date AUD$5.3 million up 46% on prior year Australia · March 2025 Quarter AUD$0.8 million down 8% on prior year · March 2025 Year to Date AUD$3.7 |
|
| April 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indi |
|
| March 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indi |
|
| March 7, 2025 |
Immuron CEO, Steven Lydeamore presentation to Coffee Microcaps Conference Exhibit 99.1 Immuron CEO, Steven Lydeamore presentation to Coffee Microcaps Conference Melbourne, Australia, March 7, 2025: Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting virtually at the Coffee Microcaps Conference on Friday 7th March 2025 (11am Australian Eastern time). A copy of the presentation being made is includ |
|
| March 5, 2025 |
Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS) Exhibit 99.1 Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS) Melbourne, Australia, March 5, 2025: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce it has entered into an exclusive distribution agreement for the territories of Australia and New Zealand in order to launch ProIBS® for the treatme |
|
| March 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indi |
|
| February 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) I |
|
| February 28, 2025 |
Exhibit 99.1 Immuron Limited Appendix 4D Half-year report 1. Company details Name of entity: Immuron Limited ABN: 80 063 114 045 Reporting period: For the period ended 31 December 2024 Previous period: For the period ended 31 December 2023 2. Results for announcement to the market $ Revenue from ordinary activities up 69.6 % to 3,994,341 Loss from ordinary activities after tax attributable to the |
|
| February 19, 2025 |
Exhibit 99.2 EMERGING GROWTH CONFERENCE 18 FEBRUARY 2025 S teven Lydeamore - CEO NASDAQ: IMRN ASX: IMC Certain statements made in this presentation are forward - looking statements and are based on Immuron’s current expectations, estimates and projections. Words such as “anticipates,” “expects,” “ intends,” “ plans,” “ believes,” “ seeks,” “estimates,” “guidance” and s imilar expressions are inten |
|
| February 19, 2025 |
Immuron CEO, Steven Lydeamore presentation to Emerging Growth Conference Exhibit 99.1 Immuron CEO, Steven Lydeamore presentation to Emerging Growth Conference Melbourne, Australia, February 19, 2025: Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore presented virtually at the Emerging Growth Conference on Tuesday 18th February 2025 (10.50am U.S. Eastern time). A copy of the presentation being made is included be |
|
| February 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) I |
|
| January 17, 2025 |
Exhibit 99.2 Appendix 2A - Application for quotation of securities Announcement Summary Entity name IMMURON LIMITED Announcement Type New announcement Date of this announcement Friday January 17, 2025 The +securities to be quoted are: +Securities issued as part of a transaction or transactions previously announced to the market in an Appendix 3B Total number of +securities to be quoted ASX +securi |
|
| January 17, 2025 |
Immuron Travelan® continued strong sales growth Exhibit 99.1 Immuron Travelan® continued strong sales growth Sales Highlights: Global ● December 2024 Quarter AUD$2.5 million up 70% on prior quarter, up 249% on pcp ● December 2024 Half Year AUD$4.0 million up 70% on pcp Australia ● December 2024 Quarter AUD$1.9 million up 83% on prior quarter, up 314% on pcp ● December 2024 Half Year AUD$2.9 million up 54% on pcp North ● December 2024 Quarter AU |
|
| January 17, 2025 |
Notice Under Section 708A(5) of the Corporations Act Exhibit 99.3 Notice Under Section 708A(5) of the Corporations Act Melbourne, Australia, January 17, 2025 This notice is given by Immuron Limited (ASX: IMC; NASDAQ: IMRN) under section 708A(5)(e) of the Corporations Act 2001 (the ‘Corporations Act’). Type Shares Class Ordinary ASX code IMC Date of Issue 15 January 2025 Number Issued 1,801,680 The Company gives notice under section 708A(5)(e) of the |
|
| January 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) In |
|
| January 15, 2025 |
Exhibit 99.2 Appendix 3B - Proposed issue of securities Announcement Summary Entity name IMMURON LIMITED Announcement Type New announcement Date of this announcement 15/1/2025 The Proposed issue is: A placement or other type of issue Total number of +securities proposed to be issued for a placement or other type of issue ASX +security code Security description Maximum Number of +securities to be i |
|
| January 15, 2025 |
Immuron Announces New Research Collaboration targeting Antimicrobial Resistance Exhibit 99.1 Immuron Announces New Research Collaboration targeting Antimicrobial Resistance Highlights: ● New Research Collaboration with Monash University ● One proposal will target Antimicrobial Resistant Pathways to develop broad spectrum therapeutic drug products ● Second project proposal will focus on the Develop of new therapeutic drug candidates against Vancomycin-resistant enterococci (VR |
|
| January 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) In |
|
| January 14, 2025 |
Immuron Announces Travelan® Clinical Trial Update Exhibit 99.1 Immuron Announces Travelan® Clinical Trial Update Highlights: ● Travelan® (IMM-124E) Phase 2 Clinical Study Report submitted to the FDA ● Travelan® (IMM-124E) Phase 2 Clinical Study Statistically Significant Immunology Results ● Travelan® (IMM-124E) Phase 2 Clinical Study Statistically Significant Microbiome Responses ● Travelan® P2TD (n=866) Uniformed Services University field study |
|
| January 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) In |
|
| January 10, 2025 |
Exhibit 99.1 Appendix 2A - Application for quotation of securities Announcement Summary Entity name IMMURON LIMITED Announcement Type New announcement Date of this announcement Friday January 10, 2025 The +securities to be quoted are: +Securities issued as part of a transaction or transactions previously announced to the market in an Appendix 3B Total number of +securities to be quoted ASX +securi |
|
| January 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) In |
|
| January 10, 2025 |
Notice Under Section 708A(5) of the Corporations Act Exhibit 99.2 Notice Under Section 708A(5) of the Corporations Act Melbourne, Australia, January 10, 2025 This notice is given by Immuron Limited (ASX: IMC; NASDAQ: IMRN) under section 708A(5)(e) of the Corporations Act 2001 (the ‘Corporations Act’). Type Shares Class Ordinary ASX code IMC Date of Issue 8 January 2025 Number Issued 2,579,760 The Company gives notice under section 708A(5)(e) of the |
|
| January 8, 2025 |
6-K 1 ea0227145-6kimmuron.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victo |
|
| January 8, 2025 |
EX-99.1 2 ea022714501ex99-1immuron.htm PROPOSED ISSUE OF SECURITIES - IMC Exhibit 99.1 Appendix 3B - Proposed issue of securities Announcement Summary Entity name IMMURON LIMITED Announcement Type New announcement Date of this announcement 8/1/2025 The Proposed issue is: A placement or other type of issue Total number of +securities proposed to be issued for a placement or other type of issue ASX |
|
| December 10, 2024 |
Appendix 3Y Change of Director’s Interest Notice Exhibit 99.3 Appendix 3Y Change of Director’s Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of Entity: Immuron Limited ABN: 80 063 114 045 We (the entity) |
|
| December 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) I |
|
| December 10, 2024 |
Appendix 3Y Change of Director’s Interest Notice Exhibit 99.2 Appendix 3Y Change of Director’s Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of Entity: Immuron Limited ABN: 80 063 114 045 We (the entity) |
|
| December 10, 2024 |
Exhibit 99.1 Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Announcement Summary Entity name IMMURON LIMITED Date of this announcement Tuesday December 10, 2024 The +securities the subject of this notification are: +Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX Total number of +securities to be iss |
|
| December 10, 2024 |
Appendix 3Y Change of Director’s Interest Notice Exhibit 99.4 Appendix 3Y Change of Director’s Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of Entity Immuron Limited ABN 80 063 114 045 We (the entity) gi |
|
| November 22, 2024 |
Immuron CEO, Steven Lydeamore presentation to 21st Virtual Investor Summit Microcap Event Exhibit 99.1 Immuron CEO, Steven Lydeamore presentation to 21st Virtual Investor Summit Microcap Event Melbourne, Australia, November 22, 2024: Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore presented early this morning at the 21st Virtual Investor Summit Microcap Event (November 21, US Eastern Time). A copy of the presentation is includ |
|
| November 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) I |
|
| November 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) I |
|
| November 18, 2024 |
Exhibit 99.1 Immuron 2024 AGM Presentation Highlights: ● Global sales increased 172% in FY24 to $4.90m; Record Travelan® sales of $4.86m ● Record monthly sales in October 2024 of $1.49m ● Completed and reported topline results for Travelan® Phase 2 and NMRC’s Campylobacter clinical trial; planning 2H2025 Phase 3 initiation for Travelan® ● Positive feedback from the FDA to IMM-529 pre-IND filing; p |
|
| November 18, 2024 |
Results of Annual General Meeting Exhibit 99.2 Results of Annual General Meeting Melbourne, Australia, November 18, 2024: Immuron Limited (ASX: IMC, NASDAQ: IMRN) advises that all resolutions considered at the Annual General Meeting held earlier today were carried by a poll. In accordance with Listing Rule 3.13.2 and Section 251AA of the Corporations Act 2001, details of the resolutions and the proxies received in respect of each |
|
| November 14, 2024 |
Appendix 3Y Change of Director’s Interest Notice Exhibit 99.2 Appendix 3Y Change of Director’s Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/9/2001. Amended 01/01/11 Name of Entity: Immuron Limited (ASX: IMC) ABN: 80 063 114 045 We |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) I |
|
| November 14, 2024 |
Exhibit 99.1 Appendix 3H - Notification of cessation of securities Announcement Summary Entity name IMMURON LIMITED Announcement Type New announcement Date of this announcement Thursday November 14, 2024 Details of +securities that have ceased ASX +security code Security description Number of +securities that have ceased The +securities have ceased due to Date of cessation IMCAD OPTION EXPIRING 13 |
|
| October 29, 2024 |
Exhibit 99.1 Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Announcement Summary Entity name IMMURON LIMITED Date of this announcement Tuesday October 29, 2024 The +securities the subject of this notification are: +Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX Total number of +securities to be issu |
|
| October 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) In |
|
| October 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) In |
|
| October 18, 2024 |
Exhibit 99.1 IMMURON LIMITED ACN 063 114 045 (ASX code: IMC, NASDAQ code: IMRN) NOTICE OF 2024 ANNUAL GENERAL MEETING AND EXPLANATORY MEMORANDUM Date and Time of Meeting: Monday, 18 November 2024 at 11.00 am Place of Meeting: The Offices of K & L Gates, Level 25, Rialto South Tower, 525 Collins Street Melbourne, Victoria And virtually at https://bit.ly/IMCAGM2024 If Shareholders are unable to atte |
|
| October 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) In |
|
| October 16, 2024 |
Immuron CEO, Steven Lydeamore participation in Maxim Virtual Healthcare Conference - addendum Exhibit 99.1 Immuron CEO, Steven Lydeamore participation in Maxim Virtual Healthcare Conference - addendum Melbourne, Australia, October 16, 2024: Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore will be participating in a fireside chat at the Maxim Virtual Healthcare Conference on Wednesday 16th October 2024 (4.30pm U.S. Eastern time). A |
|
| October 15, 2024 |
Immuron Travelan® continued strong sales growth Exhibit 99.1 Immuron Travelan® continued strong sales growth Sales Highlights: Global ● September 2024 Quarter AUD$1.5 million up 13% on prior quarter Australia ● September 2024 Quarter AUD$1.0 million up 3% on prior quarter North America ● September 2024 Quarter AUD$0.5 million up 48% on prior quarter Melbourne, Australia, October 15, 2024: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian |
|
| October 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) In |
|
| October 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) In |
|
| October 8, 2024 |
Exhibit 99.2 Appendix 2A - Application for quotation of securities Announcement Summary Entity name IMMURON LIMITED Announcement Type New announcement Date of this announcement Tuesday October 08, 2024 The +securities to be quoted are: +Securities issued, transferred or re-classified as a result of options being exercised or other +convertible securities being converted Total number of +securities |
|
| October 8, 2024 |
Notice Under Section 708A(5) of the Corporations Act Exhibit 99.1 Notice Under Section 708A(5) of the Corporations Act Melbourne, Australia, October 8, 2024 This notice is given by Immuron Limited (ASX: IMC; NASDAQ: IMRN) under section 708A(5)(e) of the Corporations Act 2001 (the ‘Corporations Act’). Type Shares Class Ordinary ASX code IMC Date of Issue 7 October 2024 Number Issued 1,147,083 The Company gives notice under section 708A(5)(e) of the C |
|
| October 4, 2024 |
NMRC Reports Results for Campylobacter Controlled Human Infection Model Study Exhibit 99.1 NMRC Reports Results for Campylobacter Controlled Human Infection Model Study Melbourne, Australia, October 4, 2024: Immuron Limited (ASX: IMC; NASDAQ: IMRN), is an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases. Following discussion with the US |
|
| October 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) In |
|
| October 1, 2024 |
Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Immuron Limited (the “Company”) on Form 20-F for the period ended June 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Philip Hains, Chief Financial Officer of the Company, cer |
|
| October 1, 2024 |
IMMURON LTD. INCENTIVE-BASED COMPENSATION RECOVERY POLICY Exhibit 97.1 IMMURON LTD. INCENTIVE-BASED COMPENSATION RECOVERY POLICY 1. Policy Purpose. The purpose of this Incentive-Based Compensation Recovery Policy (the “Policy”) is to enable Immuron Ltd. (the “Company”) to recover Erroneously Awarded Compensation in the event that the Company is required to prepare an Accounting Restatement. This Policy is intended to comply with the requirements set fort |
|
| October 1, 2024 |
CERTIFICATION OF CHIEF EXECUTIVE OFFICER Exhibit 12.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER Pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as amended I, Steven Lydeamore, certify that: 1. I have reviewed this annual report on Form 20-F of Immuron Limited; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statement |
|
| October 1, 2024 |
Exhibit 4.6 Executive employment agreement This executive employment agreement is made on 05 May 2022 between Immuron Limited ACN 063 114 045 of Unit 10, 25-37 Chapman Street, Blackburn North, VIC 3130, Australia (Employer) and Steven Lydeamore (Executive). BACKGROUND A. The Employer has decided to appoint a Chief Executive Officer (CEO) and has further decided to offer the position to the Executi |
|
| October 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 193 |
|
| October 1, 2024 |
DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT Exhibit 2(d) DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT Memorandum And Articles of Association Our Constitution Our Constitution is similar in nature to the bylaws of a U. |
|
| October 1, 2024 |
Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Immuron Limited (the “Company”) on Form 20-F for the period ended June 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Steven Lydeamore, Chief Executive Officer of the Company, |
|
| October 1, 2024 |
CERTIFICATION OF CHIEF FINANCIAL OFFICER Exhibit 12.2 CERTIFICATION OF CHIEF FINANCIAL OFFICER Pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as amended I, Philip Hains, certify that: 1. I have reviewed this annual report on Form 20-F of Immuron Limited; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements ma |
|
| September 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) |
|
| September 26, 2024 |
Exhibit 99.1 Immuron CEO, Steven Lydeamore presentation to Emerging Growth Conference Melbourne, Australia, September 26 2024: Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore presented virtually at the Emerging Growth Conference early on 26 September 2024 (AEST) (25 September 2024, U.S. Eastern Standard Time). A copy of the presentation b |
|
| September 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) |
|
| September 9, 2024 |
Attributable to owners of Immuron Limited Exhibit 99.1 Immuron Limited Appendix 4E 30 June 2024 Immuron Limited Appendix 4E Preliminary Final Report Year ended 30 June 2024 Name of entity: Immuron Limited ABN: 80 063 114 045 year ended: 30 June 2024 Previous period: 30 June 2023 Results for announcement to the market $ Revenue from ordinary activities Up 171.7% to 4,902,865 Loss from ordinary activities after tax attributable to members U |
|
| September 5, 2024 |
Immuron Plans Phase 2 Trial for IMM-529 following FDA review Exhibit 99.1 Immuron Plans Phase 2 Trial for IMM-529 following FDA review Key Points ● Immuron completes pre-IND meeting with FDA on the development of IMM-529 as product to specifically prevent or treat Clostridioides difficile infection (CDI) ● Previous clinical trial data on IMM-529 provides support for continued development of IMM-529 ● Investigational new drug (IND) application for IMM-529 pl |
|
| September 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) |
|
| August 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Ind |
|
| August 21, 2024 |
Immuron CEO, Steven Lydeamore presentation at Peak Biotech Showcase Exhibit 99.1 Immuron CEO, Steven Lydeamore presentation at Peak Biotech Showcase Melbourne, Australia, August 21 2024: Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting at Peak Biotech Showcase on Wednesday 21st August 2024 at Work Club Olderfleet, 477 Collins Street, Melbourne, Australia. A copy of the presentation being |
|
| August 16, 2024 |
Exhibit 99.1 Immuron Announces New U.S. Department of Defense Research Award for Naval Medical Research Command and Walter Reed Army Institute of Research to advance Travelan® Highlights: $3.5 (USD $2.3) million funding for NMRC and WRAIR approved by the U.S. Department of Defense to advance the development of Travelan. Melbourne, Australia, August 16, 2024: Immuron Limited (ASX: IMC; NASDAQ: IMRN |
|
| August 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Ind |
|
| August 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Ind |
|
| August 9, 2024 |
Immuron CEO, Steven Lydeamore webinar on MarketOpen Direct Connect Exhibit 99.1 Immuron CEO, Steven Lydeamore webinar on MarketOpen Direct Connect Melbourne, Australia, August 8, 2024: Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore will be hosting a webinar on MarketOpen Direct Connect on Thursday 8th August 2024, 11:00am AEST (9:00am AWST). This webinar can be viewed live via zoom & you register for FR |
|
| August 7, 2024 |
Immuron CEO, Steven Lydeamore to host webinar on MarketOpen Direct Connect Exhibit 99.1 Immuron CEO, Steven Lydeamore to host webinar on MarketOpen Direct Connect Melbourne, Australia, August 7, 2024: Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to invite shareholders to attend an investor webinar on MarketOpen Direct Connect to be held on Thursday 8th August 2024, 11:00am AEST (9:00am AWST). Chief Executive Officer, Steven Lydeamore will provide an update on addi |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Ind |
|
| July 18, 2024 |
IMMURON LIMITED Level 3, 62 Lygon Street Carlton South, Victoria, 3053, Australia IMMURON LIMITED Level 3, 62 Lygon Street Carlton South, Victoria, 3053, Australia July 17, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F. |
|
| July 18, 2024 |
Immuron CEO, Steven Lydeamore to present at Emerging Growth Conference Exhibit 99.1 Immuron CEO, Steven Lydeamore to present at Emerging Growth Conference Melbourne, Australia, July 18, 2024: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting virtually at the Emerging Growth Conference on July 18th. A copy of the presentat |
|
| July 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indic |
|
| July 15, 2024 |
Immuron Travelan® record sales globally, Australia and USA Exhibit 99.1 Immuron Travelan® record sales globally, Australia and USA Sales Highlights: Global ● FY 2024 AUD$4.9 million up 174% on prior comparative period (pcp) ● June 2024 Quarter AUD$1.3 million up 253% on pcp and 6% on prior quarter Australia ● FY 2024 AUD$3.7 million up 223% on pcp ● June 2024 Quarter AUD$1.0 million up 200% on pcp and 11% on prior quarter USA ● FY 2024 Record sales of AUD |
|
| July 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indic |
|
| July 9, 2024 |
Immuron CEO, Steven Lydeamore to present at Sharewise Exhibit 99.1 Immuron CEO, Steven Lydeamore to present at Sharewise Melbourne, Australia, July 9, 2024: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting at Sharewise on Tuesday 9 July 2024, 11:00am AEST. A copy of the presentation being made is include |
|
| July 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indic |
|
| July 5, 2024 |
Immuron CEO, Steven Lydeamore to present at Sharewise Exhibit 99.1 Immuron CEO, Steven Lydeamore to present at Sharewise Melbourne, Australia, July 4, 2024: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting at Sharewise, to be held on Tuesday 9 July 2024, 11:00am AEST. Chief Executive Officer, Steve Lydea |
|
| July 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indic |
|
| July 3, 2024 |
AT THE MARKET OFFERING AGREEMENT July 2, 2024 Exhibit 1.2 AT THE MARKET OFFERING AGREEMENT July 2, 2024 H.C. Wainwright & Co., LLC 430 Park Avenue, 3rd Floor New York, New York 10022 Ladies and Gentlemen: Immuron Limited, a corporation incorporated under the laws of Australia (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows: 1. Definitions. The terms that follow, when used i |
|
| July 3, 2024 |
AT THE MARKET OFFERING AGREEMENT July 2, 2024 Exhibit 1.1 AT THE MARKET OFFERING AGREEMENT July 2, 2024 H.C. Wainwright & Co., LLC 430 Park Avenue, 3rd Floor New York, New York 10022 Ladies and Gentlemen: Immuron Limited, a corporation incorporated under the laws of Australia (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows: 1. Definitions. The terms that follow, when used i |
|
| July 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indic |
|
| July 3, 2024 |
Exhibit 107 Calculation of Filing Fee Table F-3 (Form Type) IMMURON LIMITED (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price (3) Fee Rate Amount of Registration Fee C |
|
| July 3, 2024 |
As filed with the Securities and Exchange Commission on July 2, 2024 As filed with the Securities and Exchange Commission on July 2, 2024 Registration No. |
|
| July 2, 2024 |
Exhibit 99.1 IMM-529 pre-IND FDA filing Melbourne, Australia, July 2, 2024: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to announce that it has filed a pre-IND (investigational new drug) application with the United States Food and Drug Administration (FDA) for IMM-529. CEO, Steven Lydeamore said, “We are excited for ou |
|
| July 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indic |
|
| June 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indic |
|
| June 5, 2024 |
Appendix 3X Initial Director’s Interest Notice Exhibit 99.2 Appendix 3X Initial Director’s Interest Notice Rule 3.19A.1 Appendix 3X Initial Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/9/2001. Name of entity Immuron Limited ABN 80 063 114 045 We (the entity) give ASX the followin |
|
| June 5, 2024 |
Appendix 3Z Final Director’s Interest Notice Exhibit 99.1 Appendix 3Z Final Director’s Interest Notice Rule 3.19A.3 Appendix 3Z Final Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/9/2001. Name of entity Immuron Limited ABN 80 063 114 045 We (the entity) give ASX the following in |
|
| May 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indica |
|
| May 31, 2024 |
Exhibit 99.1 Immuron CEO, Steven Lydeamore to present at Peak Sky High Melbourne, Australia, May 31, 2024: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting at Peak Asset Management’s Peak Sky High luncheon in Melbourne on June 1st. A copy of the prese |
|
| May 31, 2024 |
Exhibit 99.2 Board Changes Melbourne, Australia, May 31, 2024: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, advises that Dr Roger Aston has resigned from his position as Non-Executive Director effective today. Roger was appointed as a Director in 2012 and served as Non-Executive Chairman from 2012 to 2023. Immuron over the past fe |
|
| May 28, 2024 |
Exhibit 99.1 Immuron Limited Appendix 4D Half-year 31 December 2023 Name of entity: Immuron Limited ABN: 80 063 114 045 Half-year ended: 31 December 2023 Previous period: 31 December 2022 Results for announcement to the market $ Revenue from ordinary activities Up 303.6% to 2,355,580 Net loss after tax (from ordinary activities) for the period attributable to members Up (4.8)% to (2,073,182 ) Net |
|
| May 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K/A REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indi |
|
| May 3, 2024 |
Exhibit 99.1 Board Change Melbourne, Australia, May 3, 2024: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, advises that Stephen Anastasiou has resigned from his position as Non- Executive Director effective today to focus on his other business interests. Stephen has served as a Director since 2013 and has provided valued contributi |
|
| May 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indica |
|
| May 3, 2024 |
Appendix 3Z Final Director’s Interest Notice Exhibit 99.2 Appendix 3Z Final Director’s Interest Notice Rule 3.19A.3 Appendix 3Z Final Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/9/2001. Name of entity Immuron Limited ABN 80 063 114 045 We (the entity) give ASX the following in |
|
| April 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indi |
|
| April 23, 2024 |
Exhibit 99.1 Immuron CEO, Steven Lydeamore to present at The Watchlist Melbourne, Australia, April 23 , 2024 : Immuron Limited (ASX : IMC ; NASDAQ : IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting at The Watchlist, to be held on Tuesday 23 rd April 2024 , 12 : 00 pm AEST/ 10 : 00 am A |
|
| April 15, 2024 |
Immuron to host Live Virtual Event Exhibit 99.1 Immuron to host Live Virtual Event Melbourne, Australia, April 15, 2024: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore together with our Chief Scientific Officer, Dr. Jerry Kanellos and Research & Development Manager, Dr. Joanne Casey will be hosting a L |
|
| April 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indi |
|
| April 10, 2024 |
Immuron Travelan® sales continued strong growth Exhibit 99.1 Immuron Travelan® sales continued strong growth Sales Highlights: Global ● FYTD Mar 2024 AUD$3.6 million up 154% on (prior comparative period) pcp ● Mar 2024 Quarter AUD$1.3 million up 51% on pcp and 75% on last quarter Australia ● FYTD Mar 2024 AUD$2.8 million up 234% on pcp ● Mar 2024 Quarter AUD$0.9 million up 66% on pcp and 99% on last quarter USA ● FYTD Mar 2024 AUD$0.8 million u |
|
| April 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indi |
|
| March 14, 2024 |
Exhibit 99.1 Immuron CEO, Steven Lydeamore to present at Coffee Microcaps Melbourne, Australia, March 14 , 2024 : Immuron Limited (ASX : IMC ; NASDAQ : IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting at the Coffee Microcaps conference in Sydney on March 14 th . A copy of the presentat |
|
| March 14, 2024 |
Total number of +securities on issue Exhibit 99.2 Appendix 2A - Application for quotation of securities Announcement Summary Entity name IMMURON LIMITED Announcement Type New announcement Date of this announcement Thursday March 14, 2024 The +securities to be quoted are: +Securities issued, transferred or re-classified as a result of options being exercised or other +convertible securities being converted Total number of +securities |
|
| March 14, 2024 |
Exhibit 99.3 |
|
| March 14, 2024 |
Notice Under Section 708A (5) of the Corporations Act Exhibit 99.4 Notice Under Section 708A (5) of the Corporations Act Melbourne, Australia, March 14, 2024 This notice is given by Immuron Limited (ASX: IMC; NASDAQ: IMRN) under section 708A(5)(e) of the Corporations Act 2001 (the ‘Corporations Act’). Type Shares Class Ordinary ASX code IMC Date of Issue 12 March 2024 Number Issued 200,000 The Company gives notice under section 708A(5)(e) of the Corp |
|
| March 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indi |
|
| March 7, 2024 |
Positive Results Support Travelan® progress to Phase 3 Clinical Trials in the US Exhibit 99.1 Positive Results Support Travelan® progress to Phase 3 Clinical Trials in the US Highlights: ● Immuron proceeding to Phase 3 registration strategy with the FDA ● Travelan® topline clinical trial results demonstrate protective efficacy with single daily dose ● 36.4% protective efficacy against Enterotoxigenic Escherichia coli (ETEC) induced moderate to severe diarrhea was observed in t |
|
| March 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indi |
|
| March 5, 2024 |
Exhibit 99.1 Market Announcement 5 March 2024 Immuron Limited (ASX: IMC) – Trading Halt Description The securities of Immuron Limited (‘IMC’) will be placed in trading halt at the request of IMC, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Thursday, 7 March 2024 or when the |
|
| March 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indi |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) I |
|
| February 28, 2024 |
Exhibit 99.1 Immuron Limited Appendix 4D Half-year 31 December 2023 Name of entity: Immuron Limited ABN: 80 063 114 045 Half-year ended: 31 December 2023 Previous period: 31 December 2022 Results for announcement to the market $ Revenue from ordinary activities Up 303.6% to 2,355,580 Net loss after tax (from ordinary activities) for the period attributable to members Up (4.8)% to (2,073,182 ) Net |
|
| February 21, 2024 |
Australian Biologics Festival 2024 Exhibit 99.1 Australian Biologics Festival 2024 Melbourne, Australia, February 21, 2024: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Research & Development Manager, Joanne Casey, PhD will be presenting at the Australian Biologics Festival 2024 on Wednesday, 21st February in Melbourne, Australia. A copy of |
|
| February 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) I |
|
| February 13, 2024 |
Immuron achieves record Travelan® sales Exhibit 99.1 Immuron achieves record Travelan® sales Highlights: ● Travelan® sales YTD Jan 2024 of $2.7 million exceed peak full year FY20 sales of $2.5 million ● Australian Travelan® YTD Jan 2024 sales $2.1 million ● USA Travelan® YTD Jan 2024 sales $0.6 million ● Canadian sales recommenced through McKesson Melbourne, Australia, February 13, 2024: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Aust |
|
| February 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) I |
|
| February 9, 2024 |
Exhibit 99.1 Investor Webinar Presentation Melbourne, Australia, February 8, 2024: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting at the Monsoon Communications Investor function on Thursday, 8th February in Sydney, Australia. A copy of the presentat |
|
| February 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) I |
|
| January 16, 2024 |
Immuron achieves record half yearly Travelan® sales Exhibit 99.1 Immuron achieves record half yearly Travelan® sales Highlights: ● Record half yearly Travelan® sales of $2,334,969 ● Total sales of A$2,355,580 in H1, FY24 o $1,771,932 increase on H1, FY23 sales o 51% higher than pre-pandemic period H1, FY20 sales Melbourne, Australia, January 16, 2024: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceu |
|
| January 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) In |
|
| December 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2023 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) I |
|
| December 22, 2023 |
Immuron Clinical Trials Update Exhibit 99.1 Immuron Clinical Trials Update Highlights: ● US Naval Medical Research Command (NMRC) campylobacter clinical program completes in-patient phase ● Manufacture of IMM-529 drug substance to support the Pre-IND information package has been completed ● Pre-IND submission to the U.S. Food and Drug administration (FDA) planned for H1 2024 ● Travelan® clinical study inpatient phase completed |
|
| December 4, 2023 |
Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study Exhibit 99.1 Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study Highlights: ● First participants enrolled in the US Naval Medical Research Command Clinical Trial ● Clinical Study initiated to evaluate the efficacy of a new Immuron clinical product to protecting volunteers against moderate to severe campylobacteriosis ● New CampETEC product is a prophylactic therape |
|
| December 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2023 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) I |
|
| November 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2023 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) I |
|
| November 28, 2023 |
Exhibit 99.1 Investor Webinar Presentation Melbourne, Australia, November 28, 2023: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to invite shareholders to attend an investor webinar “Coffee Microcaps Morning Meeting”, to be held on Tuesday 30th November 2023, 9:00am ADEST. CEO, Steven Lydeamore will provide an overview a |
|
| November 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2023 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) I |
|
| November 22, 2023 |
Exhibit 99.1 Constitution of Immuron Limited ACN 063 114 045 [Amended at a Meeting of Shareholders held on Tuesday 21 November 2023] Table of Contents 1. Definitions and interpretation 1 1.1 Definitions 1 1.2 Interpretation 2 1.3 Replaceable rules 3 1.4 Compliance with the Act 3 1.5 Transitional 4 1.6 Listing Rules and ASX Settlement Operating Rules only apply if Company is listed 4 1.7 Constituti |
|
| November 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2023 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) I |
|
| November 21, 2023 |
Exhibit 99.1 1 1 AGM PRESENTATION 21 NOVEMBER , 2023 NASDAQ: IMRN ASX: IMC Steven Lydeamore - CEO 2 2 Certain statements made in this presentation are forward - looking statements and are based on Immuron’s current expectations, estimates and projections. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “guidance” and similar expressions are intended to |
|
| November 21, 2023 |
Results of Annual General Meeting Exhibit 99.2 Results of Annual General Meeting Melbourne, Australia, November 21, 2023: Immuron Limited (ASX: IMC, NASDAQ: IMRN) advises that resolutions 1, 2, 4, 5 and 6 considered at the Annual General Meeting held earlier today were carried by a poll. Resolution 3, Approval of increased placement capacity, was not passed. In accordance with Listing Rule 3.13.2 and Section 251AA of the Corporati |
|
| November 13, 2023 |
Exhibit 99.1 Investor Webinar Presentation Melbourne, Australia, November 13, 2023: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to invite shareholders to attend an investor webinar on The Watchlist, to be held on Tuesday 14th November 2023, 1:00pm AEDT/ 10:00am AWST. CEO, Steven Lydeamore will provide an overview and up |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2023 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) I |
|
| October 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2023 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) In |
|
| October 30, 2023 |
Immuron CEO, Steven Lydeamore to present at AusBioInvest Exhibit 99.1 Immuron CEO, Steven Lydeamore to present at AusBioInvest Melbourne, Australia, October 30, 2023: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting at AusBioInvest 2023 on Monday, October 30th in the 9.40am – 10.35am session (AEST) at the P |
|
| October 23, 2023 |
Exhibit 99.1 IMMURON LIMITED ACN 063 114 045 (ASX code: IMC, NASDAQ code: IMRN) NOTICE OF 2023 ANNUAL GENERAL MEETING AND EXPLANATORY MEMORANDUM Date and Time of Meeting: 21 November 2023 at 10.00 am Place of Meeting: The Offices of K & L Gates, Level 25, Rialto South Tower, 525 Collins Street Melbourne, Victoria And virtually at https://bit.ly/IMCAGM2023 If Shareholders are unable to attend the M |
|
| October 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2023 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) In |
|
| October 18, 2023 |
Travelan® Clinical Study Cohort 2 commences Exhibit 99.1 Travelan® Clinical Study Cohort 2 commences Highlights: ● Second cohort of 34 healthy volunteers enrolled in the Travelan® Clinical Trial ● Clinical Trial to examine a dosing regimen for Travelan® more suited to the US military has commenced the second cohort ● The clinical study 6 month follow up of Cohorts 1 and 2 anticipated to be completed in April 2024 ● Travelan® is known to pro |
|
| October 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2023 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) In |
|
| October 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2023 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) In |
|
| October 11, 2023 |
Immuron achieves record quarterly Travelan® sales Exhibit 99.1 Immuron achieves record quarterly Travelan® sales Highlights: · Record quarterly Travelan® sales of $1,550,240 · Total sales of A$1,565,767 in Q1, FY24 o $1,508,933 increase on Q1, FY23 sales o 130% higher than pre-pandemic period Q1, FY20 sales Melbourne, Australia, October 11, 2023: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutic |
|
| October 4, 2023 |
Exhibit 99.1 Immuron CEO, Steven Lydeamore to present at LD Micro Melbourne, Australia, October 4 , 2023 : Immuron Limited (ASX : IMC ; NASDAQ : IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting at the 16 th annual LD Micro Main Event on Wednesday, October 4 th at 11 : 00 PT at the Luxe |
|
| October 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2023 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) In |
|
| September 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 193 |
|
| September 28, 2023 |
Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Immuron Limited (the “Company”) on Form 20-F for the period ended June 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Steven Lydeamore, Chief Executive Officer of the Company, |
|
| September 28, 2023 |
Exhibit 99.2 Immuron Limited Corporate Governance Statement 30 June 2023 This Corporate Governance Statement of Immuron Limited (the “Company”) is prepared in accordance with ASX Listing Rule 4.10.3. It is for the financial year ended 30 June 2023 and is accurate and up to date as at 28 September 2023 and has been approved by the Board. Contents Introduction Principle 1: Lay solid foundations for |
|
| September 28, 2023 |
DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT Exhibit 2(d) DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT Memorandum and Articles of Association Our Constitution Our Constitution is similar in nature to the bylaws of a U. |
|
| September 28, 2023 |
Exhibit 99.1 Corporate Governance Immuron Limited and its Board of Directors are committed to implementing and achieving an effective corporate governance framework. Our Corporate Governance Statement can be found on our website at www.immuron.com.au. Content Chairman’s letter 3 Review of operations and activities 5 Form 20-F 8 Consolidated Financial Statements 103 Auditor’s Independence Declarati |
|
| September 28, 2023 |
Exhibit 4.13 Executive employment agreement This executive employment agreement is made on 05 May 2022 between Immuron Limited ACN 063 114 045 of Unit 10, 25-37 Chapman Street, Blackburn North, VIC 3130, Australia (Employer) and Steven Lydeamore (Executive). BACKGROUND A. The Employer has decided to appoint a Chief Executive Officer (CEO) and has further decided to offer the position to the Execut |
|
| September 28, 2023 |
CERTIFICATION OF CHIEF FINANCIAL OFFICER Exhibit 12.2 CERTIFICATION OF CHIEF FINANCIAL OFFICER Pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as amended I, Philip Hains, certify that: 1. I have reviewed this annual report on Form 20-F of Immuron Limited; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements ma |
|
| September 28, 2023 |
CERTIFICATION OF CHIEF EXECUTIVE OFFICER Exhibit 12.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER Pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as amended I, Steven Lydeamore, certify that: 1. I have reviewed this annual report on Form 20-F of Immuron Limited; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statement |
|
| September 28, 2023 |
Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Immuron Limited (the “Company”) on Form 20-F for the period ended June 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Philip Hains, Chief Financial Officer of the Company, cer |
|
| September 28, 2023 |
Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Exhibit 99.3 Rules 4.7.3 and 4.10.3 Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Name of entity Immuron Limited ABN/ARBN Financial year ended: 80 063 114 045 30 June 2023 Our corporate governance statement1 for the period above can be found at:2 ☐ These pages of our annual report: ☒ This URL on our website: www.immuron.com.au/corporate-directory-and-go |
|
| September 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2023 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) |
|
| September 13, 2023 |
Immuron achieves record monthly Travelan® sales Exhibit 99.1 Immuron achieves record monthly Travelan® sales Highlights: ● Record monthly Travelan® sales ● Australian sales of A$1.18 M in August 2023 (7984% increase on August 2022 sales) Melbourne, Australia, September 13, 2023: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce record monthly sales (unaudited n |
|
| September 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2023 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) |
|
| September 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2023 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) |
|
| September 11, 2023 |
Immuron CEO, Steven Lydeamore to present at H.C. Wainwright Exhibit 99.1 Immuron CEO, Steven Lydeamore to present at H.C. Wainwright Melbourne, Australia, September 11, 2023: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting virtually at the H.C. Wainwright 25th Annual Global Investment Conference on September |
|
| August 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2023 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Ind |
|
| August 30, 2023 |
Exhibit 99.1 Immuron Limited Appendix 4E 30 June 2023 Immuron Limited Appendix 4E Preliminary Final Report Year ended 30 June 2023 Name of entity: ABN: Year ended: Previous period: Immuron Limited 80 063 114 045 30 June 2023 30 June 2022 Results for announcement to the market $ Revenue from ordinary activities Up 135.8 % to 1,804,705 Loss from ordinary activities after tax attributable to members |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2023 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Ind |
|
| August 14, 2023 |
Immuron to present at the Military Health System Research Symposium Exhibit 99.1 Immuron to present at the Military Health System Research Symposium Melbourne, Australia, August 14, 2023: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce that it will be presenting at The Military Health System Research Symposium (MHSRS), in Kissimmee, Florida from the 14th to the 17th of August 20 |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2023 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Ind |
|
| August 9, 2023 |
Immuron Receives TGA GMP Clearance Exhibit 99.1 Immuron Receives TGA GMP Clearance Highlights: ● Immuron Receives TGA GMP Clearance ● Immuron to release and dispatch Travelan® to customers this week Melbourne, Australia, August 9, 2023: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce that the Therapeutic Goods Administration (TGA) has given GMP C |
|
| July 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2023 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indic |
|
| July 25, 2023 |
Immuron Announces First Patients Enrolled in Travelan® Clinical Study Exhibit 99.1 Immuron Announces First Patients Enrolled in Travelan® Clinical Study Highlights: ● First cohort of 30 healthy volunteers enrolled in the Travelan® Clinical Trial ● Clinical Trial to examine a dosing regimen for Travelan® more suited to the US military has commenced ● Final 30 participants anticipated to be enrolled and commence the study in October 2023 ● Travelan® is known to protec |
|
| July 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2023 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indic |
|
| July 24, 2023 |
Immuron CEO, Steven Lydeamore to present at Bioshares Exhibit 99.1 Immuron CEO, Steven Lydeamore to present at Bioshares Melbourne, Australia, July 24, 2023: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting at the 17th Bioshares Biotech Summit in Hobart on July 24th. A copy of the presentation being made |
|
| July 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2023 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indic |
|
| July 11, 2023 |
Exhibit 99.1 Letter to Shareholders Highlights: ● Ateria has launched Juvia™ containing breakthrough natural ingredient ERME™ in Australia ● New clinical study is underway with the NHS in Swansea, Wales in people diagnosed with IBS due to malfermentation of carbohydrates in the gut. Melbourne, Australia, July 11, 2023 Dear Immuron Limited Shareholders (ASX: IMC; NASDAQ: IMRN), Immuron is pleased t |
|
| July 6, 2023 |
Immuron FY23 Sales increase 136% on FY22 Sales Exhibit 99.1 Immuron FY23 Sales increase 136% on FY22 Sales Highlights: ● Australian FY23 sales of A$1.16 M (478% increase on FY22 sales) ● USA FY23 Travelan® sales of A$643 k (28% increase on FY22 sales) ● Global FY23 sales of A$1.80 M (136% increase on FY22 sales) Melbourne, Australia, July 5, 2023: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmace |
|
| July 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2023 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indic |
|
| June 30, 2023 |
Exhibit 99.1 Immuron Chairman Transition Melbourne, Australia, June 30, 2023: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to announce the transition of Paul Brennan from Non-Executive Director to Chairman, effective July 1, 2023. Dr Roger Aston will continue on the Board, transitioning from Chairman to Non-Executive Di |
|
| June 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2023 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indic |
|
| June 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2023 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indic |
|
| June 22, 2023 |
Exhibit 99.1 Letter to Shareholders Highlights: ● Immuron Board approves IMM-529 cGMP manufacturing and to proceed with FDA pre-IND submission ● Recruitment and screening update for Travelan® Controlled Human Infection Model (CHIM) Clinical Trial Melbourne, Australia, June 22, 2023 Dear Immuron Limited Shareholders (ASX: IMC; NASDAQ: IMRN), Immuron is pleased to announce that it has approved proce |
|
| June 7, 2023 |
Immuron CEO, Steven Lydeamore presents at LD Micro Exhibit 99.1 Immuron CEO, Steven Lydeamore presents at LD Micro Melbourne, Australia, June 7, 2023: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore, presented at the LD Micro Invitational XIII conference at the Luxe Sunset Boulevard Hotel, Los Angeles, California, Unit |
|
| June 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2023 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indic |
|
| May 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2023 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indica |
|
| May 30, 2023 |
Immuron Initiates Recruitment of Travelan® Clinical Study Exhibit 99.1 Immuron Initiates Recruitment of Travelan® Clinical Study Highlights: ● Immuron receives approval from U.S. Army Medical Research and Development Command ● Recruitment and screening of healthy volunteers for Travelan® Controlled Human Infection Model (CHIM) Clinical Trial is in progress ● Clinical Trial to examine a dosing regimen for Travelan® more suited to the US military will comm |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2023 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indica |
|
| May 8, 2023 |
Exhibit 99.1 Immuron Announces FDA Removed Clinical Hold on New Campylobacter ETEC Therapeutic Paves way for Clinical Trial Initiation Highlights: ● U.S. Food and Drug administration (FDA) remove clinical hold on New Campylobacter ETEC Therapeutic IND application ● US Naval Medical Research Centre (NMRC) satisfactorily addressed all clinical hold issues identified by the FDA ● IND to evaluate the |
|
| May 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2023 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indica |
|
| May 2, 2023 |
Exhibit 99.1 Immuron CEO, Steven Lydeamore to present at Coffee Microcaps Melbourne, Australia, May 2 , 2023 : Immuron Limited (ASX : IMC ; NASDAQ : IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to provide a copy of the presentation bei |
|
| April 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2023 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indi |
|
| April 19, 2023 |
Q3 FY23 Business Update Presentation Exhibit 99.1 Q3 FY23 Business Update Presentation Melbourne, Australia, April 19, 2023: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases) is pleased to provide the Q3 FY23 Investor Presentation for the business updat |
|
| April 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2023 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indi |
|
| April 6, 2023 |
Immuron Q3 Sales reach 150% of 1H Sales Exhibit 99.1 Immuron Q3 Sales reach 150% of 1H Sales Highlights: ● Australian Q3 FY23 sales of A$577 k (201% of 1H sales) ● North American Q3 FY23 Travelan® sales of A$298 k (100% of 1H sales) ● Global Q3 YTD FY23 sales of A$1.46 M represent an increase of 239% compared with the corresponding period in FY22 of A$430 k Melbourne, Australia, April 6, 2023: Immuron Limited (ASX: IMC; NASDAQ: IMRN), a |
|
| February 28, 2023 |
Exhibit 99.1 1 1 INVESTOR PRESENTATION BUSINESS UPDATE 28 FEBRUARY, 2023 NASDAQ: IMRN ASX: IMC Steven Lydeamore - CEO 2 2 Certain statements made in this presentation are forward - looking statements and are based on Immuron’s current expectations, estimates and projections . Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “guidance” and similar expres |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2023 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) I |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2023 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) I |
|
| February 28, 2023 |
Immuron Limited ABN 80 063 114 045 Interim financial report for the half-year 31 December 2022 Exhibit 99.1 Immuron Limited Appendix 4D Half-year 31 December 2022 Name of entity: Immuron Limited ABN: Half-year ended: Previous period: 80 063 114 045 31 December 2022 31 December 2021 Results for announcement to the market $ Revenue from ordinary activities Up 152.7% to 583,646 Net loss after tax (from ordinary activities) for the period attributable to members Up (9.2)% to (1,978,383 ) Net lo |
|
| February 15, 2023 |
Immuron CEO, Steven Lydeamore to host an investor webinar Echibit 99.1 Immuron CEO, Steven Lydeamore to host an investor webinar Melbourne, Australia, February 15, 2023: Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, invites investors to join a live webcast hosted by Stev |
|
| February 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2023 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) I |
|
| January 25, 2023 |
Exhibit 99.1 Immuron US DoD Naval Medical Research Center responds to FDA Clinical Hold for New Campylobacter ETEC Therapeutic Melbourne, Australia, January 25, 2023: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases |
|
| January 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2023 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) In |
|
| January 18, 2023 |
Exhibit 99.1 US Department of Defense Uniformed Services University Clinical Evaluation of Travelan™ Achieves 150 Recruitment Milestone Highlights: ● First participants enrolled in USU Travelan Clinical Trial Field Study ● 157 participants successfully randomized into the Clinical Study ● Plans in place to enrol in 1302 healthy volunteers in total ● Infectious diarrhea is the most common illness r |
|
| January 18, 2023 |
6-K 1 ea171820-6kimmuron.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2023 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victor |
|
| January 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2023 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) In |
|
| January 17, 2023 |
Exhibit 99.1 Immuron Receives European Patent on Drug Composition to Treat Clostridioides difficile Associated Disease Melbourne, Australia, January 17, 2023: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is plea |
|
| December 23, 2022 |
Immuron Receives FDA Approval for Travelan IND Application Exhibit 99.1 Immuron Receives FDA Approval for Travelan IND Application Highlights: ? Immuron receives U.S. Food and Drug administration (FDA) approval for Travelan Investigational New Drug (IND) application ? IND to evaluate the efficacy of a single dose of Travelan to prevent infectious diarrhea caused by ETEC is now active ? Plans in place to initiate a Human clinical trial in 60 healthy volunt |
|
| December 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2022 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) I |
|
| December 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2022 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) I |
|
| December 5, 2022 |
Immuron Submits IND Application To FDA for Travelan EX-99.1 2 ea169623ex99-1immuron.htm IMC - IMMURON SUBMITS IND APPLICATION TO FDA FOR TRAVELAN Exhibit 99.1 Immuron Submits IND Application To FDA for Travelan Highlights: ● Investigational New Drug (IND) application submitted to the U.S. Food and Drug administration (FDA) ● Plans in place to initiate a Human clinical trial in 60 healthy volunteers in the USA ● Clinical Trial to examine a dosing re |
|
| December 1, 2022 |
Exhibit 99.1 Constitution of Immuron Limited ACN 063 114 045 Amended at a Meeting of Shareholders held on Monday 21st November 2022 Table of Contents 1. Definitions and interpretation 1 1.1 Definitions 1 1.2 Interpretation 3 1.3 Replaceable rules 3 1.4 Compliance with the Act 3 1.5 Transitional 4 1.6 Listing Rules and ASX Settlement Operating Rules only apply if Company is listed 4 1.7 Constitutio |
|
| December 1, 2022 |
6-K 1 ea169513-6kimmuron.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2022 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victo |
|
| November 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2022 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) I |
|
| November 21, 2022 |
Exhibit 99.1 AGM PRESENTATION 21 NOVEMBER, 2022 Steven Lydeamore - CEO NASDAQ: IMRN ASX: IMC 1 Certain statements made in this presentation are forward - looking statements and are based on Immuron?s current expectations, estimates and projections . Words such as ?anticipates,? ?expects,? ?intends,? ?plans,? ?believes,? ?seeks,? ?estimates,? ?guidance? and similar expressions are intended to ident |
|
| November 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2022 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) I |
|
| November 21, 2022 |
IMC - Results of Annual General Meeting EX-99.1 2 ea169048ex99-1immuron.htm IMC - RESULTS OF ANNUAL GENERAL MEETING Exhibit 99.1 |
|
| November 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2022 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) I |
|
| November 16, 2022 |
Immuron completes strategic investment in leading gut health biotech Ateria Health EX-99.1 2 ea168806ex99-1immuron.htm IMC - IMMURON COMPLETES STRATEGIC INVESTMENT IN ATERIA HEALTH Exhibit 99.1 Immuron completes strategic investment in leading gut health biotech Ateria Health Highlights: ● Immuron has completed settlement of strategic investment in leading gut health biotech Ateria Health, in accordance with signed subscription and option agreement (announced 13 October 2022): o |
|
| October 26, 2022 |
Exhibit 99.1 Level 3, 62 Lygon Street, Carlton South, Victoria AUSTRALIA 3053 www.immuron.com ABN: 80 063 114 045 Phone: + 61 (0)3 9824 5254 Facsimile: + 61 (0)3 9822 7735 Immuron CEO, Steven Lydeamore to present at AusBioInvest Melbourne, Australia, October 27 , 2022 : Immuron Limited (ASX : IMC ; NASDAQ : IMRN), an Australian based and globally integrated biopharmaceutical company that has devel |
|
| October 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2022 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) In |
